日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Global advances and future directions in lung cancer care: expert consensus and strategic priorities

全球肺癌治疗进展及未来方向:专家共识和战略重点

Meyer, M-L; Peters, S; Jänne, P A; Mok, T S; Bunn, P A; Abdel Karim, N; Altorki, N K; Arrieta, O; Bar, J; Cappuzzo, F; Carbone, D; Dacic, S; Diehn, M; Dziadziuszko, R; Felip, E; Flores, R; Florez, N; Forde, P M; Gainor, J F; Gray, J E; Gros, L; Halmos, B; Henschke, C I; Herbst, R; Heymach, J V; Kelly, K; Kris, M G; Leighl, N B; Mathias, C; Marron, T U; Mulshine, J L; Naidoo, J; Osarogiagbon, R; Passaro, A; Peled, N; Planchard, D; Politi, K; Popat, S; Pyenson, B; Reckamp, K L; Ren, S H; Riely, G J; Rolfo, C; Rudin, C M; Sen, T; Shields, M D; Singh, H; Skoulidis, F; Solomon, B J; Stahel, R; Stiles, B M; Syrigos, K; Yang, J C-H; Yang, P-C; Wolf, A; Wozniak, A J; Waqar, S N; Wakelee, H; Hirsch, F R

Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC

度伐利尤单抗联合放化疗治疗不可切除的III期非小细胞肺癌的真实世界5年疗效

Girard, N; Bar, J; Baas, P; Chouaid, C; Christoph, D C; Field, J K; Fietkau, R; Garassino, M C; Garrido Lopez, P; Gregorc, V; Haakensen, V D; Hiltermann, T J N; Kao, S; McDonald, F; Mornex, F; Moskovitz, M; Peters, S; Siva, S; Solomon, B; Qiao, Y; Anand, S; Chander, P; Shcherbakova, T; Diaz Perez, I; Filippi, A R

Prevalence, persistence, and severity of 12-month and 30-day DSM-5 disorders in the World Mental Health Hong Kong Study

世界精神卫生香港研究中DSM-5精神障碍的12个月和30天患病率、持续时间和严重程度

Wong, Corine S M; Leung, Candi M C; Wu, Shiyi; Flores, Francis P; Kim, Yoona; Xiao, Xiao; Wong, Solomon B K; Chang, Wing Chung; Chan, Wai Chi; Yu, Nancy Xiaonan; Cheng, Calvin P W; Chung, Albert K K; Lee, Edwin H M; Chiu, Wai Tat; Axinn, William G; Kessler, Ronald C; Ni, Michael Y

Immune response kinetics to SARS-CoV-2 infection and COVID-19 vaccination among nursing home residents-Georgia, October 2020-July 2022

2020年10月至2022年7月,佐治亚州养老院居民对SARS-CoV-2感染和COVID-19疫苗接种的免疫反应动力学

Chisty, Zeshan A; Li, Deana D; Haile, Melia; Houston, Hollis; DaSilva, Juliana; Overton, Rahsaan; Schuh, Amy J; Haynie, Jenn; Clemente, Jacob; Branch, Alicia G; Arons, Melissa M; Tsang, Clarisse A; Pellegrini, Gerald J Jr; Bugrysheva, Julia; Ilutsik, Justina; Mohelsky, Romy; Comer, Patricia; Hundia, Solomon B; Oh, Hyungseok; Stuckey, Matthew J; Bohannon, Caitlin D; Rasheed, Mohammed Ata Ur; Epperson, Monica; Thornburg, Natalie J; McDonald, L Clifford; Brown, Allison C; Kutty, Preeta K

Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations

在分子富集人群的靶向治疗试验中,治疗效果与缓解率、无进展生存期和总生存期之间的相关性

Solomon, B J; Loong, H H; Summers, Y; Thomas, Z M; French, P; Lin, B K; Sashegyi, A; Wolf, J; Yang, J C-H; Drilon, A

Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer

转移性非小细胞肺癌患者获得性免疫治疗耐药的临床定义

Schoenfeld, A J; Antonia, S J; Awad, M M; Felip, E; Gainor, J; Gettinger, S N; Hodi, F S; Johnson, M L; Leighl, N B; Lovly, C M; Mok, T; Perol, M; Reck, M; Solomon, B; Soria, J-C; Tan, D S W; Peters, S; Hellmann, M D

Current highlights in lung cancer in 2021

2021年肺癌研究的最新进展

Lim, K H J; Solomon, B J

Impact of COVID-19 on cancer service delivery: a follow-up international survey of oncology clinicians

COVID-19 对癌症服务提供的影响:一项针对肿瘤临床医生的国际后续调查

Chazan, G; Franchini, F; Alexander, M; Banerjee, S; Mileshkin, L; Blinman, P; Zielinski, R; Karikios, D; Pavlakis, N; Peters, S; Lordick, F; Ball, D; Wright, G; IJzerman, M; Solomon, B J

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

克唑替尼治疗 ROS1 重排的晚期非小细胞肺癌 (NSCLC):PROFILE 1001 研究的最新结果,包括总生存期

Shaw, A T; Riely, G J; Bang, Y-J; Kim, D-W; Camidge, D R; Solomon, B J; Varella-Garcia, M; Iafrate, A J; Shapiro, G I; Usari, T; Wang, S C; Wilner, K D; Clark, J W; Ou, S-H I

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

免疫检查点抑制剂治疗伴有致癌驱动基因突变的晚期肺癌患者:来自 IMMUNOTARGET 注册研究的结果

Mazieres, J; Drilon, A; Lusque, A; Mhanna, L; Cortot, A B; Mezquita, L; Thai, A A; Mascaux, C; Couraud, S; Veillon, R; Van den Heuvel, M; Neal, J; Peled, N; Früh, M; Ng, T L; Gounant, V; Popat, S; Diebold, J; Sabari, J; Zhu, V W; Rothschild, S I; Bironzo, P; Martinez-Marti, A; Curioni-Fontecedro, A; Rosell, R; Lattuca-Truc, M; Wiesweg, M; Besse, B; Solomon, B; Barlesi, F; Schouten, R D; Wakelee, H; Camidge, D R; Zalcman, G; Novello, S; Ou, S I; Milia, J; Gautschi, O